Health secretary Robert F. Kennedy Jr. yesterday appointed a new, smaller vaccine advisory committee at the CDC — just two ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

In the trial, 120 patients with atopic dermatitis and skin of color (82% Black, 11% Asian, 2% American Indian/Alaska Native, 5% Arab, Central American or other) were treated with Dupixent every two ...